Evidence map›Paper›PMID 38588337›Full record

ArticleCirculation2024

Right Ventricular Bone-Avid Tracer Uptake: A Novel Risk Marker in Transthyretin Amyloid Cardiomyopathy.

Sharmila Dorbala

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Sharmila DorbalaDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Cardiac Amyloidosis Program, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0003-1462-1185

Funding

Interplay of Myocardial Fibrosis and Cardiac TTR Amyloid in Age Related Cardiac Remodeling in MESA-Multi-Ethnic Study of AtherosclerosisR01HL159987 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI DORBALA, SHARMILA, LIMA, JOAO A C · 2022 to 2025
$5.6M
Early Detection of Transthyretin Cardiac Amyloidosis: Defining a Novel Target for HFpEF Treatment and Prevention in Late LifeR01HL150342 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI DORBALA, SHARMILA, SHAH, AMIL M · 2020 to 2023
$4.1M
Prognostic Utility of Absolute Coronary Microvascular Function by PET/CTK23HL092299 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI DORBALA, SHARMILA · 2009 to 2013
$705k
Mentoring Patient Oriented Research in Innovative Imaging and High-dimensional Data Approaches to Improve Outcomes in Cardiac AmyloidosisK24HL157648 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI DORBALA, SHARMILA · 2021 to 2025
$612k
NHLBI NIH HHS K23 HL092299NHLBI NIH HHS K24 HL157648NHLBI NIH HHS R01 HL150342NHLBI NIH HHS R01 HL159987
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AmyloidosisCardiomyopathiesHumansPrealbuminPrognosisRadionuclide ImagingPrealbumincardiomyopathiesEditorialstomography, emission-computed, single-photontransthyretin

Identifiers

PMID38588337
PMCPMC11216712

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.